Drug Profile
XEN 801
Alternative Names: XEN801Latest Information Update: 01 Oct 2021
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Class Antiacnes; Skin disorder therapies; Small molecules
- Mechanism of Action Stearoyl CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne vulgaris; Skin disorders
Most Recent Events
- 01 Oct 2021 Discontinued - Phase-II for Acne vulgaris in Canada (Topical) (Xenon Pharma pipeline, October 2021)
- 01 Oct 2021 Discontinued - Preclinical for Skin disorders in Canada (unspecified route) (Xenon Pharma pipeline, October 2021)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Skin-disorders in Canada